Protalix BioTherapeutics Inc (PLX) Unusual Options Activity Today

Checking PLX unusual options activity helps you spot when traders are making outsized bets on Protalix BioTherapeutics Inc before the broader market catches on. Protalix BioTherapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor PLX unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching PLX unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking PLX unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and PLX unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases.

The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Catalysts rarely arrive without a footprint, and PLX unusual options activity is often where that footprint shows up first. Our scanner tracks Protalix BioTherapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at PLX unusual options volume on the call side or chasing put sweeps, Protalix BioTherapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.